FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Check this box if no longer subject	S
to Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  TRENARY C RUSSELL III					2. Issuer Name and Ticker or Trading Symbol Outlook Therapeutics, Inc. [ OTLK ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
IIVEIV	IKI CK	OJJELL III										_		X	Direc	tor		10% O	wner	
(Last)	(Fir	st) (N	Middle)		3. Da	Date of Earliest Transaction (Month/Day/Year)								X	Office belov	cer (give title w)		Other ( below)	specify	
485 ROUTE 1 SOUTH, BUILDING F					12/06/2021								CEO and President							
SUITE 320					1															
3011E 320						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable						
(Street)					,	4. If Americanient, Date of Original Fried (World Day) Teal)								Line)						
ISELIN	NJ	0	8830		1									X	Form	filed by One	e Rep	orting Pers	on	
,															Form filed by More than One Reporting Person					
(City)	(Sta	ate) (Z	<u>z</u> ip)																	
		Table	I - No	n-Deriva	tive S	Secu	rities	Acq	uired	, Dis	posed of	, or E	Benefi	icially	/ Own	ed				
1. Title of Security (Instr. 3)  2. Transacti Date (Month/Day						Execution Date,			3. 4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)				4 and Securi Benefi Owned		ties cially I Following	Form (D) o	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) (D)	or Pri	ce		action(s) 3 and 4)			(Instr. 4)	
Common Stock 12/0			12/06/2	2021				P		25,000	A	\$1	L.39 <sup>(1)</sup>	35,000			D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
				(e.g., pu	its, ca	alls, v	warra	ants,	optio	ns, c	onvertib	le se	curiti	es)						
1. Title of Derivative Security (Instr. 3)	ve Conversion Date Execution Date, or Exercise (Month/Day/Year) if any		ion Date,	4. Transaction Code (Instr. 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Insti 3 and 4)		De Se (In	Price of rivative curity str. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	or Number of Shares	er						

## **Explanation of Responses:**

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$1.37 to \$1.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

## Remarks:

/s/ Lawrence Kenyon, 12/06/2021 Attorney-in-Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.